Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Lung Transplant
When do you entertain a diagnosis of HLA-negative antibody mediated rejection in lung transplant recipients?
Related Questions
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
How do you approach induction immunosuppression in patients with high PRA undergoing lung transplantation?
What factors influence your decision to initiate antifungal treatment in asymptomatic lung transplant recipients colonized with Aspergillus?
How do you integrate dd-cfDNA into the evaluation and management of ACR in lung transplant recipients?
What is the current practice regarding the use of GLP-1 agonists in patients listed for lung transplant and in the post-transplant period?
How do you manage MAT for opioid use disorder in lung transplant patients during the peri/postoperative period?
Do you consider early belatacept based immunosuppression in lung transplant recipients?
How has the FLUID trial, which showed no significant difference in death or readmission rates between Lactated Ringer’s solution and normal saline, influenced your approach to IV fluid management?
Do you have any pearls for how to manage OSA with CPAP in older adults with cognitive impairment?
Is the recommended duration of anticoagulation different for provoked DVT compared to provoked PE?
